耐受性
医学
来曲唑
药效学
药代动力学
内科学
不利影响
肿瘤科
胶质瘤
恶心
临床试验
药理学
癌症
芳香化酶
乳腺癌
癌症研究
作者
Pankaj B. Desai,Aniruddha S. Karve,Misam Zawit,Priyanka Arora,Nimita Dave,Joy Awosika,Ningjing Li,Bethany Fuhrman,Mario Medvedovic,Larry Sallans,Ady Kendler,Biplab Dasgupta,David R. Plas,Richard Curry,Mario Zuccarello,Rekha Chaudhary,Soma Sengupta,Trisha M. Wise‐Draper
标识
DOI:10.1158/1078-0432.ccr-23-3341
摘要
High-grade gliomas (HGG) carry a poor prognosis, with glioblastoma accounting for almost 50% of primary brain malignancies in the elderly. Unfortunately, despite the use of multiple treatment modalities, the prognosis remains poor in this population. Our preclinical studies suggest that the presence of aromatase expression, encoded by CYP19A1, is significantly upregulated in HGGs. Remarkably, we find that letrozole (LTZ), an FDA-approved aromatase inhibitor, has marked activity against HGGs.
科研通智能强力驱动
Strongly Powered by AbleSci AI